Lower CREM expression was associated with a higher risk of metastasis as well as a poorer response to cisplatin, a treatment used in ESCC among many other cancers.8 Further studies are warranted to demonstrate the mechanisms behind altered CREM expression, and the consequences thereof, in other forms of cancer. The gene discussed is CREM; the disease is cancer.